Table 4

Overall and cancer specific survival

Reference		Intercurrent deaths (%)		n		Clinical subset		Median survival (months)	Overall survival (%)			Cancer specific survival (%)		Disease free survival (%)
Reference		Intercurrent deaths (%)		n		Clinical subset		Median survival (months)	1 year	2 year	3 year	5 year	1 year	2 year	3 year	5 year	2 year	5 year
Stage I (T1–2N0)
Haffty (1998)⁸	NS	43		28			36	21
		11	Continuous	52				45
		32	Split	27				12
Sandler (1990)10	13	77		20			17				22
		25	<3 cm				25				30
		41	3–6 cm				13				17
		9	>6 cm				0				0
Ono (1991)11	NS	38		NS	84	68	55	42
Kaskowitz (1993)12	25	53		21		43	19	6		54	33	13
Slotman (1994)13	43	47		20	70		33	15	90		53	32
Gauden (1995)14	12	347		28		54	40	27					41	23
		167	T1					32
		180	T2					21
Park (1995)15	NS	15		15		22		0
Krol (1996)16	30	108		23	75	49	31	15	81	58	42	31
		89	⩽4 cm				35				40
		19	>4 cm				11				13
Slotman (1996)17	42	31		33	81	72	42	8		93	76^4-a
Morita (1997)18	13	149		27	78		34	22
			<4 cm					25
			>4 cm					17
Jeremic (1997)19	12	49		33				30						41
		25	T1	40		76		37
		24	T2	24		50		24
Nguyen-Tan (1998)20	20	41		23		41
		19	T1	26		63
		22	T2	14		24
Sibley (1998)21	33	141		18		39		13		60		32
Hayakawa (1999)22	NS	36		NS			42	23			56	39

Stage IIA (T1–2N1)
Salloum (1990)23	NS	61		18				22
Rosenthal (1992)24	NS	62		18	70	33	20	12
			PS 0–1	23	83	49	28
			PS 2–3	6

Stage I & IIA (T1–2N0–1)
Zhang (1989)25	14	42		NS	93		52	31
Schildge (1993)27	NS	67		17	55		19	5
		35	NCRF		69		21	11
Graham (1995)28	25	103		16		35		13
		35	T1^4-b					29
		68	T2^4-b					4
Koukourakis (1995)29	NS	64	NTD	NS
			56–64 Gy											30
			48–55 Gy											12
Furuta (1996)30	34	32		NS		40		16		57		36	43	23
Hayakawa (1996)31	NS	84		NS
		28	T1–2N0			74		31
		56	T1–2N1			40		19
		48	<5 cm					29
		36	⩾5 cm					14
Saunders (1999),⁶ Bentzen (2000)⁷	NS	169	60 Gy CHART	NS		24 37	12 ^4-a 18 ^4-a
Anderson (2000)34	NS	36		12	50	22		6

Stage I & IIB (T1–3N0)
Talton (1990)35	NS	77		18	56	37	21	17
Dosoretz (1992),36 (1993)37	11	152				40								9
		44	T1	NR									55
		63	T2	12									20
		41	T3	12									25
Dosoretz (1993)37			T1 60–65Gy										29 ^c
			T1 >65 Gy										90 ^c
Dosoretz (1996)38		245		16				7					28	9
			<3 cm										38
			>5 cm										23
Kupelian (1996)39	NS	19	T1	NS							49
		26	T2								47
		14	T3								26

Intercurrent deaths are deaths known not to be due to cancer (where reported), shown as a percentage of the number of patients undergoing treatment.
NS = not stated; NR = not reached; NCRF = normal cardiorespiratory function.
↵4-a 4 year survival;
↵4-b only 10% of each subgroup had N1 disease;
4-c 3 year disease free survival.
Randomised trial shown in bold; results of subgroup analyses shown in italics.